Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Diseases (3)
- Pathology (3)
- Life Sciences (2)
- Pharmacology (2)
- Pharmacology, Toxicology and Environmental Health (2)
-
- Biodiversity (1)
- Cell Biology (1)
- Cell and Developmental Biology (1)
- Hematology (1)
- Hemic and Lymphatic Diseases (1)
- Immunology and Infectious Disease (1)
- Immunology of Infectious Disease (1)
- Male Urogenital Diseases (1)
- Medical Sciences (1)
- Otolaryngology (1)
- Otorhinolaryngologic Diseases (1)
- Reproductive and Urinary Physiology (1)
- Urology (1)
- Keyword
-
- CTCL (1)
- Clinical trial (1)
- Cytogenetics (1)
- DAB389IL-2 (1)
- Fibro osseous tissue (1)
-
- Fusion protein (1)
- Growth factors (1)
- IL-2IL-2R (1)
- Immunophenotypic analysis (1)
- Ion channels (1)
- Lymphoma (1)
- Medical-specialty; business-industry (1)
- Nasal cavity (1)
- Neoplasms (1)
- Non-Hodgkin's lymphoma (1)
- Oncogenes (1)
- Ossifying fibroma (1)
- Prostatic neoplasms (1)
- Pulmonary and respiratory medicine; oncology; cancer research; medicine (1)
- Retinoic acid syndrome (1)
- Tumour (1)
Articles 1 - 6 of 6
Full-Text Articles in Oncology
Ossifying Fibroma Of Nasal Cavity, Abbas Zafar Abbas Zafar, Muhammad Shafi Muhammad Shafi, Shaukat Malik Shaukat Malik, Shahid Pervez
Ossifying Fibroma Of Nasal Cavity, Abbas Zafar Abbas Zafar, Muhammad Shafi Muhammad Shafi, Shaukat Malik Shaukat Malik, Shahid Pervez
Department of Pathology and Laboratory Medicine
No abstract provided.
Molecular And Cellular Biology Of Prostate Cancer, El-Nasir Lalani, Marc Elie Laniado, Paul David Abel
Molecular And Cellular Biology Of Prostate Cancer, El-Nasir Lalani, Marc Elie Laniado, Paul David Abel
Department of Pathology and Laboratory Medicine
Prostate cancer is an enigmatic disease. Although prostatic-intraepithelial neoplasia appears as early as the third decade and as many as 80% of 80 year old men have epithelial cells in their prostate that fit the morphological criteria for cancer, only about 10% of men will ever have the clinical disease and less than 3% will die from it. There have been no significant proven interventions which have altered the natural history of the disease since hormone down regulation was introduced in the 1940s and new research has been poorly supported. There is however an urgent need to develop new criteria …
Immunophenotypic Analysis Of Non-Hodgkin's Lymphoma, Suhail Muzaffar, Shahid Pervez, Farrukh Aijaz, Syed Abdul Aziz, Sheema H. Hasan
Immunophenotypic Analysis Of Non-Hodgkin's Lymphoma, Suhail Muzaffar, Shahid Pervez, Farrukh Aijaz, Syed Abdul Aziz, Sheema H. Hasan
Department of Pathology and Laboratory Medicine
One hundred and three cases of Non-Hodgkin’s lymphoma were evaluated immunohistochemically using a panel of monoclonal antibodies which includes leucocyte common antigen (LCA), CD45R (Pan-B marker), L-26 (CD 20-Pan-B marker) and UCHL-1 (Pan-T marker). Of the total 63 cases (61.17%) showed a B-cell phenotype while 40(38.83%) were of T-cell origin. Most B-cell neoplasms belonged to intermediate (79.36%) or high grade (15.87%) according to the international Working Formulation (WF). Most T- cell lymphomas were of either intermediate (52.5%) or high grade (32.5%) neoplasms. Some T-cell neoplasms presented as specific clinicopathological entities like lymphomatoid granulomatosis (2 cases), mycosis fungoides (1 case) and …
Retinoic Acid Syndrome Radiological Features, M. Umar Islam, Ikram A. Burney, Mohammad Khurshid
Retinoic Acid Syndrome Radiological Features, M. Umar Islam, Ikram A. Burney, Mohammad Khurshid
Section of Haematology/Oncology
No abstract provided.
Interleukin-2 Fusion Protein: An Investigational Therapy For Interleukin-2 Receptor Expressing Malignancies, Jean Nichols, Foss Francine, Kuzel Timothy, Lemaistre Charles Fred, Platanias Leonidas, Ratain Mark, Rook Alain, Mansoor Saleh, Schwartz Gary
Interleukin-2 Fusion Protein: An Investigational Therapy For Interleukin-2 Receptor Expressing Malignancies, Jean Nichols, Foss Francine, Kuzel Timothy, Lemaistre Charles Fred, Platanias Leonidas, Ratain Mark, Rook Alain, Mansoor Saleh, Schwartz Gary
Haematology and Oncology, East Africa
DAB3s91L-2 is an interleukin-2 receptor (IL-2R) specific fusion protein with a molecular weight of 58 kD containing the enzymatic and translocation domains of diphtheria toxin (DT) and human IL-2. This fusion protein is able to direct the cytocidal action of the DT enzymatic region only to cells which bear the IL-2R. The human IL-2R exists in three forms: low, intermediate and high affinity. The high-affinity form is believed to be the biologically relevant form on mature, activated T-lymphocytes, B-lymphocytes and monocytes. DAB3sgIL-2 is able to bind selectively to the high-affinity IL-2R in a concentration-dependent manner, and once bound is internalised …
503 Phase I Radioimmunotherapy (Rit) Study Of 90y-Cc49 Monoclonal Antibody (Mab) Therapy In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc), Francisco Robert, Ruby Meredith, Michael Khazaeli, Charles Russell, William Grizzle, John Newsome, Mansoor Saleh
503 Phase I Radioimmunotherapy (Rit) Study Of 90y-Cc49 Monoclonal Antibody (Mab) Therapy In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc), Francisco Robert, Ruby Meredith, Michael Khazaeli, Charles Russell, William Grizzle, John Newsome, Mansoor Saleh
Haematology and Oncology, East Africa
503 Phase I radioimmunotherapy (RIT) study of 90Y-CC49 monoclonal antibody (MAb) therapy in patients with advanced non-small cell lung cancer (NSCLC) × Close The Infona portal uses cookies, ie strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms …